Jan 08, 2024 / 05:00PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
All right. Let's get started. Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, [LaRhea Hall] and Malcolm Kuno. Our next presenting company is Sarepta, and presenting on behalf of the company, we have CEO, Doug Ingram. Doug?
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you. Thank you, Anupam, and thank you all, both in the room and on the Internet for joining us today. Appreciate that. We will be making some forward-looking statements, so please look to our public filings for the various risks and uncertainties that come whenever one makes predictions about the future. There's a lot one can say about Sarepta. We set for ourselves very big goals always with the patient as our North Star. We lead from our perspective.
We challenge convention when necessary, we execute. And what I'd like to do in the short
Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot